Menu Search
Equities

Aton SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3HB:FRA

Aton SA

Actions
  • Price (EUR)0.0026
  • Today's Change0.000 / -7.14%
  • Shares traded500.00
  • 1 Year change-61.19%
  • Beta0.1428
Data delayed at least 15 minutes, as of Feb 10 2026 07:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aton SA, formerly known as Hybrigenics SA is France-based Company engaged in the biotechnological sector. It specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The Company is specialized in the research and development (R&D) of drugs to fight cancer. It is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. It operates through Hybrigenics Corporation and Imaxio.

  • Revenue in EUR (TTM)--
  • Net income in EUR--
  • Incorporated1998
  • Employees9.00
  • Location
    Aton SA850 Boulevard Sebastien BrantILLKIRCH-GRAFFENSTADEN 67400FranceFRA
  • Phone+33 158103800
  • Fax+33 158103849
  • Websitehttps://www.aton-group.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.